Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
Joint trajectories of obesity and depressive symptoms and risk of incident glaucoma: a 16-year prospective cohort study from the Health and Retirement Study
Alfasigma gains arthritis drug, access to new markets with M&A play
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas
Legend interim CEO talks rising competition as Carvykti maker posts first profit
Leo Pharma readies rare disease education push for 2nd annual GPP awareness day
Neurocrine stands by blockbuster hopeful Vykat XR as Prader-Willi docs raise potential safety flags
Obesity not a 'zero-sum game' as patients crave optionality, Novo CEO says: Reuters
AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
It's crunch time for Karyopharm as company faces potential default next month
Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
A genomics library for the AI era
Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision
It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
Danish politicians call out Eli Lilly obesity campaign
Argenx heads to FDA with Vyvgart after ph. 3 win in potential blockbuster autoimmune indication
Sanofi to lay off 229 Blueprint Medicines staffers, close Cambridge offices following acquisition
ASTRAZENECA PLC · ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER
CompaniesAstraZeneca PLCAssetsENHERTUDiseasesHER2-mutated lung cancer
Related coverage (2) — shares extracted facts, not the same cluster
ASTRAZENECA PLC · UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL
CompaniesAstraZeneca PLCAssetsvolrustomigDiseasesmetastatic non-small cell lung cancer
ASTRAZENECA PLC · TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG
CompaniesAstraZeneca PLCAssetsTagrissoOrlopatysDiseasesEGFR mutation lung cancer